Reversal of a rocuronium-induced grade IV anaphylaxis via early injection of a large dose of sugammadex.

Can J Anaesth

Département « Anesthésie -Douleur », Centre Hospitalier Régional Universitaire de Caremeau, Nîmes, Faculté de Médecine Montpellier-Nîmes, Université Montpellier I, Montpellier, France.

Published: June 2014

Aim: To report rapid recovery from grade IV rocuronium-induced anaphylaxis with a large dose of sugammadex administered early after the onset of symptoms.

Clinical Features: A 22-yr-old female without relevant medical history developed an anaphylactic reaction within three minutes of rocuronium injection at induction of anesthesia for a routine cholecystectomy. During the first six minutes, she was unresponsive to usual treatment and her condition evolved to a grade IV anaphylaxis reaction despite a cumulated dose of epinephrine 0.7 mg. Sugammadex 14 mg·kg(-1), injected six minutes after rocuronium, resulted in total resolution of all manifestations of anaphylaxis within three minutes. The patient was discharged from hospital the next day. Allergy investigations confirmed rocuronium as the cause of anaphylaxis.

Conclusion: Very early administration of a large dose of sugammadex may be an effective treatment for rocuronium-induced anaphylaxis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12630-014-0148-3DOI Listing

Publication Analysis

Top Keywords

large dose
12
dose sugammadex
12
grade anaphylaxis
8
rocuronium-induced anaphylaxis
8
three minutes
8
minutes rocuronium
8
anaphylaxis
5
reversal rocuronium-induced
4
rocuronium-induced grade
4
anaphylaxis early
4

Similar Publications

Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas.

Methods: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years.

View Article and Find Full Text PDF

How to monitor the side effects of treatments in cancer patients.

Curr Opin Oncol

January 2025

DIOPP, Gustave Roussy Cancer Campus, Villejuif, France.

Purpose Of Review: Monitoring the side effects of treatments in cancer patients is a key challenge in clinical practice, especially with the development of oral therapies.The impact on patients is multifaceted: morbidity or even life-threatening risks in the case of severe side effects; deterioration in quality of life and functional abilities; lower adherence to treatments; reduced dose intensity, which can affect the efficacy of therapies.

Recent Findings: The availability of digital tools for remote patient monitoring is transforming our ability to track these patients effectively.

View Article and Find Full Text PDF

Psychedelics engage the serotonergic system as potent neuromodulators, increasing neuroplasticity in humans and rodents. Persistent changes in cognitive flexibility, emotional regulation, and social cognition are thought to underlie the therapeutic effects of psychedelics. However, the underlying molecular and cellular basis of psychedelic-induced plasticity remains unclear.

View Article and Find Full Text PDF

Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity.

Clin Cosmet Investig Dermatol

January 2025

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations.

View Article and Find Full Text PDF

Purpose: Mitoxantrone (MTX) is largely restricted in clinical usage due to its significant cardiotoxicity. Multiple studies have shown that an imbalance in the gut-heart axis plays an important role in the development of cardiovascular disease (CVD). We aim to explore the possible correlations between gut microbiota (GM) compositions and cardiometabolic (CM) disorder in MTX-triggered cardiotoxicity mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!